ArticlePloS one2017
16S rRNA gene sequencing and healthy reference ranges for 28 clinically relevant microbial taxa from the human gut microbiome.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Pooled it
- Trial
- Tart Cherry Concentrate Does Not Alter the Gut Microbiome, Glycaemic Control or Systemic Inflammation in a Middle-Aged Population.Nutrients · 2019Trial
- Hidden Gut Dysbiosis in Apparently Healthy Adults.Life (Basel, Switzerland) · 2026Article
- Effect of Probiotics on the Gut-Mammary Pathway: Implications on Infant Microbiota Transfer and Development.Current nutrition reports · 2026Review
- Elevated Lactobacillus salivarius and genus Akkermansia in fecal samples of Taiwanese patients with parkinson's disease and diabetes mellitus.Scientific reports · 2025Article
- Next-generation probiotics and engineered BEVs for precision therapeutics in osteoporosis.Frontiers in nutrition · 2025Review
- Comprehensive analysis of gut microbiota and fecal metabolites in patients with autism spectrum disorder.Frontiers in microbiology · 2025Article
- Comparing the Microbiome of the Adenoids in Children with Secretory Otitis Media and Children without Middle Ear Effusion.Microorganisms · 2024Article
- Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease.Cell host & microbe · 2024Article
- Microbiome and pregnancy: focus on microbial dysbiosis coupled with maternal obesity.International journal of obesity (2005) · 2024Review
- Gut microbiota are differentially correlated with blood pressure status in African American collegiate athletes: A pilot study.Physiological reports · 2024Article
- Bioprocessing strategies for enhanced probiotic extracellular vesicle production: culture condition modulation.Frontiers in bioengineering and biotechnology · 2024Article
- Article
- A bioinformatic analysis of zinc transporters in intestinal Lactobacillaceae.Metallomics : integrated biometal science · 2023Article
- Microbiota Profile of the Nasal Cavity According to Lifestyles in Healthy Adults in Santiago, Chile.Microorganisms · 2023Article
- Article
- Human leukocyte antigen-dependent colonization ofFrontiers in microbiomes · 2023Article
- Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light.Current treatment options in oncology · 2022Review
- Fecal sphingolipids predict parenteral nutrition-associated cholestasis in the neonatal intensive care unit.JPEN. Journal of parenteral and enteral nutrition · 2022Article
Corrections and comments
- Expression of concern · 2022-10-20Concerns/Issues about Data · Investigation by Journal/Publisher ·
- Erratum issued
- Expression of concern
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Changes in the relative abundances of many intestinal microorganisms, both those that naturally occur in the human gut microbiome and those that are considered pathogens, have been associated with a range of diseases. To more accurately diagnose health conditions, medical practitioners could benefit from a molecular, culture-independent assay for the quantification of these microorganisms in the context of a healthy reference range. Here we present the targeted sequencing of the microbial 16S rRNA gene of clinically relevant gut microorganisms as a method to provide a gut screening test that could assist in the clinical diagnosis of certain health conditions. We evaluated the possibility of detecting 46 clinical prokaryotic targets in the human gut, 28 of which could be identified with high precision and sensitivity by a bioinformatics pipeline that includes sequence analysis and taxonomic annotation. These targets included 20 commensal, 3 beneficial (probiotic), and 5 pathogenic intestinal microbial taxa. Using stool microbiome samples from a cohort of 897 healthy individuals, we established a reference range defining clinically relevant relative levels for each of the 28 targets. Our assay quantifies 28 targets in the context of a healthy reference range and correctly reflected 38/38 verification samples of real and synthetic stool material containing known gut pathogens. Thus, we have established a method to determine microbiome composition with a focus on clinically relevant taxa, which has the potential to contribute to patient diagnosis, treatment, and monitoring. More broadly, our method can facilitate epidemiological studies of the microbiome as it relates to overall human health and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.